Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
262 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03780725 | This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05741372 | A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis | completed | N/A | 28 | Boehringer IngelheimINDUSTRY | 1 | Jan 13, 2026 |
| clinicaltrials |
| NCT01856478 | LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | completed | Phase 3 | 340 | Boehringer IngelheimINDUSTRY | 8 | Jan 12, 2026 | clinicaltrials |
| NCT06058793 | Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 3 | 138 | Boehringer IngelheimINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT03433898 | This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer | completed | Early Phase 1 | 146 | Boehringer IngelheimINDUSTRY | 3 | Dec 19, 2025 | clinicaltrials |
| NCT03468426 | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | completed | Phase 1 | 252 | Boehringer IngelheimINDUSTRY | 12 | Nov 10, 2025 | clinicaltrials |
| NCT03972150 | A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer | completed | Phase 1 | 21 | Boehringer IngelheimINDUSTRY | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02674152 | Dose Finding Study of BI 836880 in Patients With Solid Tumors | completed | Phase 1 | 29 | Boehringer IngelheimINDUSTRY | 2 | Oct 1, 2025 | clinicaltrials |
| NCT02689505 | Weekly BI 836880 in Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | Boehringer IngelheimINDUSTRY | 2 | Oct 1, 2025 | clinicaltrials |
| NCT04147234 | A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) | completed | Phase 1 | 42 | Boehringer IngelheimINDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT00716417 | Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours | completed | Phase 1 | 47 | Boehringer IngelheimINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02392455 | VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC) | completed | — | 817 | Boehringer IngelheimINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT01403974 | Phase I Trial of BI 836845 for Various Solid Cancer | completed | Phase 1 | 61 | Boehringer IngelheimINDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT02123823 | BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer | completed | Phase 1 | 164 | Boehringer IngelheimINDUSTRY | 10 | Jul 15, 2025 | clinicaltrials |
| NCT02204072 | BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 | 120 | Boehringer IngelheimINDUSTRY | 8 | Jul 15, 2025 | clinicaltrials |
| NCT01317420 | Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types | completed | Phase 1 | 64 | Boehringer IngelheimINDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT06115681 | Real-world Study of Dedifferentiated Liposarcoma Patients in China | completed | — | 1,390 | Boehringer IngelheimINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02191891 | Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 32 | Boehringer IngelheimINDUSTRY | 4 | Jun 25, 2025 | clinicaltrials |
| NCT02145741 | Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours | completed | Phase 1 | 21 | Boehringer IngelheimINDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03464045 | Empa PASS on Urinary Tract Malignancies | completed | — | 344,995 | Boehringer IngelheimINDUSTRY | 3 | Apr 20, 2025 | clinicaltrials |
| NCT01853826 | An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) | completed | Phase 3 | 481 | Boehringer IngelheimINDUSTRY | 11 | Apr 11, 2025 | clinicaltrials |
| NCT04137289 | A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 110 | Boehringer IngelheimINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT05446129 | A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery | terminated | Phase 1 | 2 | Boehringer IngelheimINDUSTRY | 1 | Mar 13, 2025 | clinicaltrials |
| NCT00979576 | BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 19 | Boehringer IngelheimINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04206787 | The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer | completed | — | 72 | Boehringer IngelheimINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT03659136 | The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | completed | Phase 2 | 103 | Boehringer IngelheimINDUSTRY | 11 | Feb 24, 2025 | clinicaltrials |
| NCT02597946 | Afatinib in NSCLC With HER2 Mutation | completed | Phase 2 | 18 | Boehringer IngelheimINDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT05087992 | A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers | completed | Phase 1 | 13 | Boehringer IngelheimINDUSTRY | 5 | Feb 19, 2025 | clinicaltrials |
| NCT01314105 | BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer | completed | Phase 1 | 19 | Boehringer IngelheimINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT02231164 | LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research | terminated | Phase 3 | 12 | Boehringer IngelheimINDUSTRY | 3 | Feb 13, 2025 | clinicaltrials |
| NCT01346540 | A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. | completed | Phase 1 | 16 | Boehringer IngelheimINDUSTRY | 4 | Feb 12, 2025 | clinicaltrials |
| NCT00748709 | Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification. | terminated | Phase 2 | 20 | Boehringer IngelheimINDUSTRY | 2 | Feb 11, 2025 | clinicaltrials |
| NCT01649271 | Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. | completed | Phase 1 | 13 | Boehringer IngelheimINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02300298 | Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy | completed | Phase 1 | 10 | Boehringer IngelheimINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT00950742 | Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer. | completed | Phase 1 | 18 | Boehringer IngelheimINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT01214616 | BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours | completed | Phase 1 | 17 | Boehringer IngelheimINDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT02780700 | Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2] | terminated | Phase 2 | 1 | Boehringer IngelheimINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT01690624 | BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT02171650 | BIBW 2992 in Patients With Advanced Solid Tumors | completed | Phase 1 | 7 | Boehringer IngelheimINDUSTRY | 0 | Jan 23, 2025 | clinicaltrials |
| NCT02182245 | Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies | completed | Phase 1 | 22 | Boehringer IngelheimINDUSTRY | 0 | Jan 23, 2025 | clinicaltrials |
| NCT02182219 | Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer | completed | Phase 1 | 21 | Boehringer IngelheimINDUSTRY | 0 | Jan 22, 2025 | clinicaltrials |
| NCT05613036 | A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body | completed | Phase 1 | 13 | Boehringer IngelheimINDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT00243087 | Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 | 41 | Boehringer IngelheimINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02211859 | Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit | completed | Phase 1 | 70 | Boehringer IngelheimINDUSTRY | 0 | Dec 20, 2024 | clinicaltrials |
| NCT03166631 | A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | terminated | Phase 1 | 62 | Boehringer IngelheimINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04138823 | A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours) | completed | Phase 1 | 12 | Boehringer IngelheimINDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT04742556 | A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) | completed | Phase 1 | 15 | Boehringer IngelheimINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials